Resumen de acción PRPH
ProPhase Labs, Inc. desarrolla y comercializa nuevos fármacos, suplementos dietéticos y compuestos en Estados Unidos.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Competidores de ProPhase Labs, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.71 |
| 52 Week High | US$9.94 |
| 52 Week Low | US$4.05 |
| Beta | -0.27 |
| 1 Month Change | -27.20% |
| 3 Month Change | -1.46% |
| 1 Year Change | -37.20% |
| 3 Year Change | -11.63% |
| 5 Year Change | 53.92% |
| Change since IPO | 842.00% |
Noticias y actualizaciones recientes
Recent updates
Does This Valuation Of ProPhase Labs, Inc. (NASDAQ:PRPH) Imply Investors Are Overpaying?
Mar 04
ProPhase Labs, Inc.'s (NASDAQ:PRPH) Business And Shares Still Trailing The Industry
Jan 09ProPhase Labs, Inc. (NASDAQ:PRPH) Shares Could Be 28% Above Their Intrinsic Value Estimate
Sep 21Here's Why ProPhase Labs (NASDAQ:PRPH) Can Afford Some Debt
Aug 11We Ran A Stock Scan For Earnings Growth And ProPhase Labs (NASDAQ:PRPH) Passed With Ease
Apr 07ProPhase Labs (NASDAQ:PRPH) Seems To Use Debt Quite Sensibly
Jan 24ProPhase Labs: Small Cap Stock With Strong Fundamentals And Growth Potential
Oct 13ProPhase Labs Q2 2022 Earnings Preview
Aug 10We Think ProPhase Labs (NASDAQ:PRPH) Can Stay On Top Of Its Debt
Jul 26ProPhase Labs to license two investigational cancer compounds from Global BioLife
Jul 21ProPhase Labs: A Stellar Quarter And Another Special Dividend
May 16ProPhase Labs (NASDAQ:PRPH) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Apr 08ProPhase Labs (NASDAQ:PRPH) Is Using Debt Safely
Mar 23Rock star Growth Puts ProPhase Labs (NASDAQ:PRPH) In A Position To Use Debt
Nov 30As Employer Vaccine Mandates Fail, Prophase Labs Could Benefit
Oct 20Calculating The Fair Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Jul 22ProPhase Labs Is A Potential Pure Play On Worries About The Delta And Delta Plus Covid-19 Variants
Jun 28Here's Why Shareholders May Consider Paying ProPhase Labs, Inc.'s (NASDAQ:PRPH) CEO A Little More
May 14ProPhase Labs partners with Dutchess County New York to provide COVID-19 testing
May 06A Look At The Intrinsic Value Of ProPhase Labs, Inc. (NASDAQ:PRPH)
Apr 12ProPhase Labs opens Covid testing facility in New York
Jan 29ProPhase Labs announces $5.5M registered direct offering of common stock and warrants
Jan 05ProPhase Labs expands COVID-19 testing capacity in New York, shares +21%
Dec 09Rentabilidad de los accionistas
| PRPH | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | -10.5% | 0.7% | 2.9% |
| 1Y | -37.2% | 10.8% | 22.2% |
Rentabilidad vs. Industria: PRPH obtuvo unos resultados inferiores a los del sector US Pharmaceuticals , que el año pasado arrojó un rendimiento del 13.2%.
Rentabilidad vs. Mercado: PRPH obtuvo unos resultados inferiores a los del mercado US, que fue del 24.9% el año pasado.
Volatilidad de los precios
| PRPH volatility | |
|---|---|
| PRPH Average Weekly Movement | 10.7% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: El precio de las acciones de PRPH ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de PRPH(11%) se ha mantenido estable durante el último año, pero sigue siendo superior al 75% de las acciones de US.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1989 | 113 | Ted Karkus | www.prophaselabs.com |
ProPhase Labs, Inc. desarrolla y comercializa nuevos fármacos, suplementos dietéticos y compuestos en Estados Unidos. Opera a través de dos segmentos: Servicios de Diagnóstico y Productos de Consumo. La empresa suministra una gama de suplementos TK, como Legendz XL, para la salud sexual masculina, y Triple Edge XL, un potenciador de la energía y la resistencia.
Resumen de fundamentos de ProPhase Labs, Inc.
| Estadísticas fundamentales de PRPH | |
|---|---|
| Capitalización bursátil | US$84.99m |
| Beneficios(TTM) | -US$16.78m |
| Ingresos (TTM) | US$44.38m |
1.9x
Ratio precio-ventas (PS)-5.1x
Ratio precio-beneficio (PE)¿Está PRPH sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de PRPH | |
|---|---|
| Ingresos | US$44.38m |
| Coste de los ingresos | US$28.15m |
| Beneficio bruto | US$16.24m |
| Otros gastos | US$33.02m |
| Beneficios | -US$16.78m |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -0.93 |
| Margen bruto | 36.59% |
| Margen de beneficio neto | -37.81% |
| Ratio deuda/patrimonio | 20.8% |
¿Cómo se ha desempeñado PRPH a largo plazo?
Ver rendimiento histórico y comparativa